Reviews Gadobenate Dimeglumine Injection


No reviews yet.

Multihance Drug Description
MultiHance
(gadobenate dimeglumine) Injection

WARNING: NEPHROGENIC SYSTEMIC FIBROSIS
NEPHROGENIC SYSTEMIC FIBROSIS Gadolinium-based contrast agents increase
the risk for nephrogenic systemic fibrosis (NSF) in patients with:

acute or chronic severe renal insufficiency (glomerular filtration rate
< 30 mL/min/1.73m²), or
acute renal insufficiency of any severity due to the hepato-renal syndrome
or in the perioperative liver transplantation period.

In these patients, avoid use of gadolinium-based contrast agents unless
the diagnostic information is essential and not available with non-contrast
enhanced magnetic resonance imaging (MRI). NSF may result in fatal or debilitating
systemic fibrosis affecting the skin, muscle and internal organs. Screen all
patients for renal dysfunction by obtaining a history and/or laboratory tests.
When administering a gadolinium-based contrast agent, do not exceed the recommended
dose and allow a sufficient period of time for elimination of the agent from
the body prior to any readministration [see WARNINGS AND PRECAUTIONS].


DRUG DESCRIPTION
MultiHance injection is supplied as a sterile, non-pyrogenic, clear, colorless,
aqueous solution intended for intravenous use only. Each mL of MultiHance contains
529 mg gadobenate dimeglumine and water for injection. MultiHance contains no
preservatives.
Gadobenate dimeglumine is chemically designated as (4RS)-[4-carboxy-5,8,11-tris(carboxymethyl)-
1-phenyl-2oxa-5,8,11-triazatridecan-13-oato(5-)] gadolinate(2-) dihydrogen compound
with 1-deoxy-1-(methylamino)-Dglucitol (1:2) with a molecular weight of 1058.2
and an empirical formula of C22H28GdN3O11•2C7H17NO5.
The structural formula is as follows:








MultiHance has a pH of 6.5-7.5. Pertinent physicochemical parameters are provided
below:




Osmolality
1.970 osmol/kg @ 37°C


Viscosity
5.3 mPas @ 37°C


Density
1.220 g/mL @ 20°C



MultiHance has an osmolality 6.9 times that of plasma (285 mOsmol/kg water)
and is hypertonic under conditions of use.
Last reviewed on RxList: 4/2/2010




Multihance Drug Description
MultiHance
(gadobenate dimeglumine) Injection

WARNING: NEPHROGENIC SYSTEMIC FIBROSIS
NEPHROGENIC SYSTEMIC FIBROSIS Gadolinium-based contrast agents increase
the risk for nephrogenic systemic fibrosis (NSF) in patients with:

acute or chronic severe renal insufficiency (glomerular filtration rate
< 30 mL/min/1.73m²), or
acute renal insufficiency of any severity due to the hepato-renal syndrome
or in the perioperative liver transplantation period.

In these patients, avoid use of gadolinium-based contrast agents unless
the diagnostic information is essential and not available with non-contrast
enhanced magnetic resonance imaging (MRI). NSF may result in fatal or debilitating
systemic fibrosis affecting the skin, muscle and internal organs. Screen all
patients for renal dysfunction by obtaining a history and/or laboratory tests.
When administering a gadolinium-based contrast agent, do not exceed the recommended
dose and allow a sufficient period of time for elimination of the agent from
the body prior to any readministration [see WARNINGS AND PRECAUTIONS].


DRUG DESCRIPTION
MultiHance injection is supplied as a sterile, non-pyrogenic, clear, colorless,
aqueous solution intended for intravenous use only. Each mL of MultiHance contains
529 mg gadobenate dimeglumine and water for injection. MultiHance contains no
preservatives.
Gadobenate dimeglumine is chemically designated as (4RS)-[4-carboxy-5,8,11-tris(carboxymethyl)-
1-phenyl-2oxa-5,8,11-triazatridecan-13-oato(5-)] gadolinate(2-) dihydrogen compound
with 1-deoxy-1-(methylamino)-Dglucitol (1:2) with a molecular weight of 1058.2
and an empirical formula of C22H28GdN3O11•2C7H17NO5.
The structural formula is as follows:








MultiHance has a pH of 6.5-7.5. Pertinent physicochemical parameters are provided
below:




Osmolality
1.970 osmol/kg @ 37°C


Viscosity
5.3 mPas @ 37°C


Density
1.220 g/mL @ 20°C



MultiHance has an osmolality 6.9 times that of plasma (285 mOsmol/kg water)
and is hypertonic under conditions of use.
Last reviewed on RxList: 4/2/2010




Multihance Drug Description
MultiHance
(gadobenate dimeglumine) Injection

WARNING: NEPHROGENIC SYSTEMIC FIBROSIS
NEPHROGENIC SYSTEMIC FIBROSIS Gadolinium-based contrast agents increase
the risk for nephrogenic systemic fibrosis (NSF) in patients with:

acute or chronic severe renal insufficiency (glomerular filtration rate
< 30 mL/min/1.73m²), or
acute renal insufficiency of any severity due to the hepato-renal syndrome
or in the perioperative liver transplantation period.

In these patients, avoid use of gadolinium-based contrast agents unless
the diagnostic information is essential and not available with non-contrast
enhanced magnetic resonance imaging (MRI). NSF may result in fatal or debilitating
systemic fibrosis affecting the skin, muscle and internal organs. Screen all
patients for renal dysfunction by obtaining a history and/or laboratory tests.
When administering a gadolinium-based contrast agent, do not exceed the recommended
dose and allow a sufficient period of time for elimination of the agent from
the body prior to any readministration [see WARNINGS AND PRECAUTIONS].


DRUG DESCRIPTION
MultiHance injection is supplied as a sterile, non-pyrogenic, clear, colorless,
aqueous solution intended for intravenous use only. Each mL of MultiHance contains
529 mg gadobenate dimeglumine and water for injection. MultiHance contains no
preservatives.
Gadobenate dimeglumine is chemically designated as (4RS)-[4-carboxy-5,8,11-tris(carboxymethyl)-
1-phenyl-2oxa-5,8,11-triazatridecan-13-oato(5-)] gadolinate(2-) dihydrogen compound
with 1-deoxy-1-(methylamino)-Dglucitol (1:2) with a molecular weight of 1058.2
and an empirical formula of C22H28GdN3O11•2C7H17NO5.
The structural formula is as follows:








MultiHance has a pH of 6.5-7.5. Pertinent physicochemical parameters are provided
below:




Osmolality
1.970 osmol/kg @ 37°C


Viscosity
5.3 mPas @ 37°C


Density
1.220 g/mL @ 20°C



MultiHance has an osmolality 6.9 times that of plasma (285 mOsmol/kg water)
and is hypertonic under conditions of use.
Last reviewed on RxList: 4/2/2010




Multihance Drug Description
MultiHance
(gadobenate dimeglumine) Injection

WARNING: NEPHROGENIC SYSTEMIC FIBROSIS
NEPHROGENIC SYSTEMIC FIBROSIS Gadolinium-based contrast agents increase
the risk for nephrogenic systemic fibrosis (NSF) in patients with:

acute or chronic severe renal insufficiency (glomerular filtration rate
< 30 mL/min/1.73m²), or
acute renal insufficiency of any severity due to the hepato-renal syndrome
or in the perioperative liver transplantation period.

In these patients, avoid use of gadolinium-based contrast agents unless
the diagnostic information is essential and not available with non-contrast
enhanced magnetic resonance imaging (MRI). NSF may result in fatal or debilitating
systemic fibrosis affecting the skin, muscle and internal organs. Screen all
patients for renal dysfunction by obtaining a history and/or laboratory tests.
When administering a gadolinium-based contrast agent, do not exceed the recommended
dose and allow a sufficient period of time for elimination of the agent from
the body prior to any readministration [see WARNINGS AND PRECAUTIONS].


DRUG DESCRIPTION
MultiHance injection is supplied as a sterile, non-pyrogenic, clear, colorless,
aqueous solution intended for intravenous use only. Each mL of MultiHance contains
529 mg gadobenate dimeglumine and water for injection. MultiHance contains no
preservatives.
Gadobenate dimeglumine is chemically designated as (4RS)-[4-carboxy-5,8,11-tris(carboxymethyl)-
1-phenyl-2oxa-5,8,11-triazatridecan-13-oato(5-)] gadolinate(2-) dihydrogen compound
with 1-deoxy-1-(methylamino)-Dglucitol (1:2) with a molecular weight of 1058.2
and an empirical formula of C22H28GdN3O11•2C7H17NO5.
The structural formula is as follows:








MultiHance has a pH of 6.5-7.5. Pertinent physicochemical parameters are provided
below:




Osmolality
1.970 osmol/kg @ 37°C


Viscosity
5.3 mPas @ 37°C


Density
1.220 g/mL @ 20°C



MultiHance has an osmolality 6.9 times that of plasma (285 mOsmol/kg water)
and is hypertonic under conditions of use.
Last reviewed on RxList: 4/2/2010




Multihance Drug Description
MultiHance
(gadobenate dimeglumine) Injection

WARNING: NEPHROGENIC SYSTEMIC FIBROSIS
NEPHROGENIC SYSTEMIC FIBROSIS Gadolinium-based contrast agents increase
the risk for nephrogenic systemic fibrosis (NSF) in patients with:

acute or chronic severe renal insufficiency (glomerular filtration rate
< 30 mL/min/1.73m²), or
acute renal insufficiency of any severity due to the hepato-renal syndrome
or in the perioperative liver transplantation period.

In these patients, avoid use of gadolinium-based contrast agents unless
the diagnostic information is essential and not available with non-contrast
enhanced magnetic resonance imaging (MRI). NSF may result in fatal or debilitating
systemic fibrosis affecting the skin, muscle and internal organs. Screen all
patients for renal dysfunction by obtaining a history and/or laboratory tests.
When administering a gadolinium-based contrast agent, do not exceed the recommended
dose and allow a sufficient period of time for elimination of the agent from
the body prior to any readministration [see WARNINGS AND PRECAUTIONS].


DRUG DESCRIPTION
MultiHance injection is supplied as a sterile, non-pyrogenic, clear, colorless,
aqueous solution intended for intravenous use only. Each mL of MultiHance contains
529 mg gadobenate dimeglumine and water for injection. MultiHance contains no
preservatives.
Gadobenate dimeglumine is chemically designated as (4RS)-[4-carboxy-5,8,11-tris(carboxymethyl)-
1-phenyl-2oxa-5,8,11-triazatridecan-13-oato(5-)] gadolinate(2-) dihydrogen compound
with 1-deoxy-1-(methylamino)-Dglucitol (1:2) with a molecular weight of 1058.2
and an empirical formula of C22H28GdN3O11•2C7H17NO5.
The structural formula is as follows:








MultiHance has a pH of 6.5-7.5. Pertinent physicochemical parameters are provided
below:




Osmolality
1.970 osmol/kg @ 37°C


Viscosity
5.3 mPas @ 37°C


Density
1.220 g/mL @ 20°C



MultiHance has an osmolality 6.9 times that of plasma (285 mOsmol/kg water)
and is hypertonic under conditions of use.
Last reviewed on RxList: 4/2/2010





Other reviews about Gadobenate Dimeglumine Injection on web:

Learn about the prescription medication Multihance (Gadobenate Dimeglumine Injection), drug uses, dosage, side effects, drug interactions, warnings, reviews and patient labeling. Multihance (Gadobenate Dimeglumine Injection) Drug Information ...


Gadobenate Dimeglumine(injection) (injectable)Multihance ... Does anyone know why I'm not allowed to donate blood? I'm nitrate dependant, and have been deferred from donating blood. Gadobenate Dimeglumine(injection) (injectable) - Drug Information ...


multihanceCI(gadobenate dimeglumine) injection, 529 mg/mL Page 1 of 12 Multihance (gadobenate dimeglumine) Injection, Solution (Bracco Diagnostics Inc.) WARING: NEPHROGENIC SYSTEMIC ... Multihance (gadobenate dimeglumine) Injection, Solution


Gadobenate Dimeglumine (gad-oh-BEN-ate di-ME-gloo-meen) Used in magnetic resonance imaging (MRI) scans. Helps your doctor to see images of your brain, spine, and other parts of your ... Gadobenate dimeglumine (Injection)


Gadobenate Dimeglumine (gad-oh-BEN-ate di-ME-gloo-meen) Used in magnetic resonance imaging (MRI ... is deep in the hip bone or ribs; or muscle weakness after you get the injection. Kelsey-Seybold Clinic - Welcome


Gadobenate Dimeglumine (gad-oh-BEN-ate di-ME-gloo-meen) Used in magnetic resonance imaging (MRI ... is deep in the hip bone or ribs; or muscle weakness after you get the injection. St. Luke's Sugar Land Hospital - Your Health Topics


Gadobenate Dimeglumine (gad-oh-BEN-ate di-ME-gloo-meen) Used in magnetic resonance imaging (MRI ... is deep in the hip bone or ribs; or muscle weakness after you get the injection. St. Luke's The Woodlands Hospital - Your Heath Topics


Gadobenate Dimeglumine (gad-oh-BEN-ate di-ME-gloo-meen) Used in magnetic resonance imaging (MRI) scans. Helps your doctor to see images of your brain, spine, and other parts of your ... Allina Hospitals & Clinics - Gadobenate dimeglumine (Injection)


Gadobenate dimeglumine (Injection) ... if you have had an allergic reaction to benzyl alcohol, gadolinium, or gadobenate dimeglumine. Health Library


Gadobenate dimeglumine (Injection): Gadobenate Dimeglumine (gad-oh-BEN-ate di-ME-gloo-meen)Used in magnetic resonance imaging (MRI) scans. Helps your doctor to see images of ... Gadobenate dimeglumine (Injection)





Featured Reviews

Reviews Buprenorphine Transdermal System

Butrans Drug Description Butrans (buprenorphine) Transdermal System for Transdermal Administration WARNING IMPORTANCE OF PROPER PATIENT SELECTION, POTENTIAL FOR ABUSE, AND LIMITATIONS OF USE Proper Patient Selection Butrans is...
Read More  |  Review This
Reviews Sacrosidase Oral Solution

Sucraid Drug Description Sucraid® (sacrosidase) Oral Solution DRUG DESCRIPTION What are the possible side effects of sacrosidase (Sucraid)? Stop using this medication and get emergency medical help if you have any of these...
Read More  |  Review This
Reviews Infasurf

Infasurf Drug Description Infasurf® (calfactant) Intratracheal Suspension DRUG DESCRIPTION What are the possible side effects of calfactant (Infasurf)? Calfactant causes few side effects. There is a possibility that the baby...
Read More  |  Review This
Reviews Erlotinib

Tarceva Drug Description TARCEVA® (erlotinib) Tablets, Oral DRUG DESCRIPTION What are the possible side effects of erlotinib (Tarceva)? If you experience any of the following serious side effects from erlotinib, contact your...
Read More  |  Review This
Reviews Dilantin

Dilantin Drug Description Dilantin® (phenytoin sodium) 100 mg Extended Oral Capsule DRUG DESCRIPTION What are the possible side effects of phenytoin? Get emergency medical help if you have any of these signs of an allergic...
Read More  |  Review This
Recent News
59sec - the BEST lead management system around!
We tested 59sec - THE lead management system and we love it. 59sec helps small and medium companies to answer leads in maximum 59 seconds. Why...
MOVEorPAY - our favorite facebook app
We do love MOVEorPAY motivational facebook app, because it is very cool and useful. It makes you finish stuff that you know are good for you, but from various reasons, you never do...
ReviewsAZ is almost ready to be officially launched
yes, we have just a few loose ends to tie and we are ready to go :) meanwhile, I am putting some reviews on the site, so people will not get an empty site at the launch....